Source study found

Story checked

Switching on healthy silent genes reveals new way to treat Prader-Willi syndrome (opens in a new tab)

medicalxpress.com · 2026-10-27

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 4 other points were not covered by the paper.

2 supported
1 overstated
4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Switching on healthy silent genes reveals new way to treat Prader-Willi syndrome

medicalxpress.com · 2026-10-27

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

One claim overstates the study. Two of seven check out. Four claims the study doesn't address.

2 supported
1 overstated
4 not covered

Open claim evidence

The source study

SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome

Science Advances · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedLead researcher Marnie Blewitt said one of the most important findings was that gene activity could be restored without causing problems elsewhere in the body, a critical step toward future treatments for babies and young children.View evidenceHide evidence

Why this verdict

The profile supports that PWS-gene activity was activated in mouse tissues and that postdevelopmental targeting appeared well tolerated or 'remarkably safe' in the reported animal-model context. But the story’s wording—'without causing problems elsewhere in the body' and as a critical step for babies and young children—goes beyond the abstract, which does not provide safety endpoints, duration, off-target details, or human/infant safety evidence. The headline safety implication is therefore stronger than the supplied paper evidence.

Study evidence

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

Study evidence

SMCHD1 exhibits broader genome-wide binding.

“Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.”

Claim 2 of 7Not coveredThe findings are published in the journal Science Advances.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include journal-publication metadata confirming publication in Science Advances. This may be true externally, but it is not verifiable from the provided abstract-level scientific profile.

Claim 3 of 7Not coveredThe discovery offers hope for a treatment that targets the underlying cause of Prader-Willi syndrome and is being advanced toward potential new medicines through WEHI spinout company Togglelux Therapeutics.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the idea that SMCHD1 is a candidate therapeutic target and that the work supports potential gene-activation therapy for PWS. However, the specific claim that the finding is being advanced toward medicines through WEHI spinout Togglelux Therapeutics is not contained in the supplied paper profile, so the full claim is not verifiable at this depth.

Study evidence

SMCHD1 represses the PWS imprinted locus in both mice and humans.

“First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target.”

Study evidence

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

Claim 4 of 7Not coveredThe team combined CRISPR gene-editing, stem-cell and genomic technologies to track what happened when SMCHD1 was removed, measuring the effects across thousands of genes and in the most disease-relevant brain tissue.View evidenceHide evidence

As statedthousands of genes

Why this verdict

The profile supports use of genetic or molecular perturbation, neural-lineage contexts, disease-relevant mouse tissues including hypothalamus, and genome-wide binding/profiling concepts. But the abstract-level profile does not verify the specific methods named by the story—CRISPR, stem-cell technologies, measuring effects across thousands of genes, or the phrase 'most disease-relevant brain tissue.' These details may be in the full paper but are not verifiable from the supplied abstract-level profile.

Study evidence

SMCHD1 represses the entire PWS imprinted locus in neural lineages, extending prior evidence of only partial-cluster repression.

“Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster.”

Study evidence

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

Claim 5 of 7Not coveredBlewitt said the strategy worked in patient-derived stem cells and animal models, and that the work is an important milestone in nearly two decades of research.View evidenceHide evidence

As statednearly two decades

Why this verdict

The profile supports activity in human systems and mouse/animal models, including phenotypic improvement in a PWS mouse model. However, it does not specify patient-derived stem cells, and it does not verify the 'nearly two decades' research-milestone claim. The animal-model component is supported, but the full story claim is not verifiable from the abstract-level profile.

Study evidence

SMCHD1 represses the PWS imprinted locus in both mice and humans.

“First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target.”

Study evidence

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

Claim 6 of 7SupportedWEHI researchers have discovered a way to release a genetic 'brake' that silences healthy genes in Prader-Willi syndrome, opening a potential new path to treating the condition.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the central framing that SMCHD1 represses the PWS locus and that postdevelopmental Smchd1 deletion can activate PWS genes in disease-relevant mouse tissues, with the paper interpreting SMCHD1 as a therapeutically relevant target. The claim is hedged as a potential treatment path, which fits the abstract evidence; it should not be read as a proven human treatment.

Study evidence

SMCHD1 represses the PWS imprinted locus in both mice and humans.

“First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target.”

Study evidence

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

Claim 7 of 7SupportedIn a new study, researchers showed that removing SMCHD1 lifts a genetic 'brake,' allowing healthy but dormant genes to switch back on.View evidenceHide evidence

Why this verdict

The profile supports a causal experimental statement that SMCHD1/Smchd1 removal or deletion lifts repression of PWS-locus genes in mouse and human systems, neural lineages, and disease-relevant mouse tissues. The claim is unhedged, but it is framed as what the study showed experimentally rather than as clinical efficacy, so it is supported at abstract depth.

Study evidence

SMCHD1 represses the PWS imprinted locus in both mice and humans.

“First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target.”

Study evidence

SMCHD1 represses the entire PWS imprinted locus in neural lineages, extending prior evidence of only partial-cluster repression.

“Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

In neural lineages, SMCHD1 represses the entire PWS locus, extending the known breadth of repression beyond part of the cluster.
The story generally refers to disease-relevant brain tissue and dormant genes, but it does not clearly convey the specific neural-lineage finding that SMCHD1 represses the entire PWS locus.
From in vitro neural-lineage perturbation with locus-wide profiling (inferred)

4 things the story did carry across

SMCHD1 represses the PWS imprinted locus in both mouse and human systems, supporting SMCHD1 as a therapeutically relevant epigenetic target.
Post–early-development conditional Smchd1 deletion in vivo activates PWS genes in disease-relevant tissues, including hypothalamus, and improves phenotypes in a PWS mouse model.
Despite broader genome-wide binding, postdevelopmental SMCHD1 targeting appeared well tolerated in the reported experimental context, supporting feasibility of gene-activation therapy.
The evidence is preclinical/basic-research evidence from experimental systems, including in vitro/neural-lineage contexts and mouse models; it is not evidence of a proven human therapy.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalPost–early-development (conditional) Smchd1 deletion in vivo activates PWS genes in disease-relevant tissues (e.g., hypothalamus) and improves phenotypes in a PWS mouse model.in vivo conditional deletion postdevelopmentExpand

In plain English

In mice, conditional deletion of Smchd1 after early development led to activation of normally silenced maternal PWS-locus genes in disease-relevant tissues (including hypothalamus) and was associated with improvement of phenotypes in a Prader–Willi syndrome mouse model; the intervention was reported to appear well tolerated despite SMCHD1's broader genome-wide binding.

Key findings

Post–early-development conditional deletion of Smchd1 in mice activated PWS-locus genes in disease-relevant tissues including the hypothalamus.
Postdevelopmental Smchd1 deletion was associated with improved phenotypes in a Prader–Willi syndrome mouse model.

“Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus…”

What this piece can’t prove

The abstract does not specify which PWS genes were activated, the cell types responsible, or the specific phenotypes that improved.

2 further details could not be confirmed from the summary.

2otherSMCHD1 represses the Prader-Willi syndrome (PWS) imprinted locus in both mouse and human systems, supporting SMCHD1 as a therapeutically relevant epigenetic target.cross-species mechanistic perturbation (mouse and human)Expand

In plain English

The authors report that the epigenetic regulator SMCHD1 represses the Prader–Willi syndrome (PWS) imprinted locus in both mouse and human experimental systems, supporting SMCHD1 as a therapeutically relevant target for activating the normally silenced maternal copy of PWS genes.

Key findings

SMCHD1 represses the PWS imprinted locus in both mice and humans.

“First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vitroIn neural lineages, SMCHD1 represses the entire PWS locus (beyond its previously known partial role), indicating lineage-relevant breadth of repression.in vitro neural-lineage perturbation with locus-wide profiling (inferred)Expand

In plain English

The authors report that, in neural lineages, SMCHD1 represses the entire Prader–Willi syndrome (PWS) imprinted locus, extending prior evidence that had implicated SMCHD1 in only part of the cluster.

Key findings

SMCHD1 represses the entire PWS imprinted locus in neural lineages, extending prior evidence of only partial-cluster repression.

“Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster.”

What this piece can’t prove

4 further details could not be confirmed from the summary.

4in vivo animalPost–early-development (conditional) Smchd1 deletion in vivo activates PWS genes in disease-relevant tissues (e.g., hypothalamus) and improves phenotypes in a PWS mouse model.In vivo mouse experiments: conditional (post–early-development) Smchd1 deletion in a PWS mouse model with subsequent tissue molecular assays and phenotypic (behavioral/physiologic) endpointsExpand

In plain English

Abstract reports that conditional, post–early-development deletion of Smchd1 in mice activates PWS locus genes in disease-relevant tissues (including hypothalamus) and is associated with improved phenotypes in a PWS mouse model, supporting SMCHD1 as a potential gene-activation therapeutic target.

Key findings

Post–early-development conditional deletion of Smchd1 in mice activated PWS genes in disease-relevant tissues (including hypothalamus) and was associated with improved phenotypes in a PWS mouse model.

“…and improved phenotypes in a PWS mouse model.”

What this piece can’t prove

Abstract does not report quantitative effect sizes or statistical measures for the reported phenotypic improvements.
The abstract summarizes both molecular and phenotypic outcomes but does not provide timing or rigor details needed to evaluate causal inference at abstract depth.

2 further details could not be confirmed from the summary.

5in vivo animalDespite broader genome-wide binding, post–early-development targeting of SMCHD1 appears remarkably safe, supporting feasibility of gene activation therapy targeting SMCHD1.in vivo postdevelopmental perturbation and genome-wide profilingExpand

In plain English

The authors report that SMCHD1 shows broader genome-wide binding yet that post–early-developmental targeting/deletion of Smchd1 in vivo appeared to be well tolerated, supporting the feasibility of SMCHD1-directed gene-activation therapy for Prader–Willi syndrome.

Key findings

SMCHD1 exhibits broader genome-wide binding.
Post–early-development targeting/deletion of Smchd1 in vivo appeared remarkably safe, supporting feasibility of SMCHD1-directed gene-activation therapy for PWS.

“Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer